William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating on February 19.
Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising potential of Solid Biosciences’ SGT-003 therapy for Duchenne muscular dystrophy (DMD). The initial results from the Phase I/II INSPIRE DUCHENNE study demonstrated significant microdystrophin expression in patients, suggesting a best-in-class capability. Notably, the expression levels recorded were twofold higher compared to other gene therapies for DMD, indicating a strong therapeutic effect.
Sami Corwin’s rating is also based on the potent performance of Solid’s proprietary AAV-SLB101 capsid. This capsid showed high dystrophin fiber positivity and a favorable vector copy number (VCN) compared to competitors, which is indicative of its efficacy. Furthermore, the lower dose requirement of SGT-003, alongside restored function of other components of the dystrophin-glycoprotein complex, reinforces the therapy’s potential and supports the positive outlook on the stock.
In another report released on February 19, Barclays also maintained a Buy rating on the stock with a $15.00 price target.